Entinostat (Not yet branded)
Other Medications
Description
Entinostat is a selective histone deacetylase (HDAC) inhibitor that has been evaluated in combination therapies for metastatic colorectal cancer, particularly in microsatellite stable (MSS) tumors. This epigenetic modifier is being tested alongside other agents like azacitidine and immunotherapy combinations to enhance treatment responses in advanced solid tumors. Entinostat represents a class of drugs that target chromatin remodeling to restore normal gene expression patterns in cancer cells.
Mechanism of Action
Entinostat selectively inhibits class I histone deacetylases, particularly HDAC1 and HDAC3, which leads to increased acetylation of histones and other proteins. This epigenetic modification results in chromatin relaxation and reactivation of tumor suppressor genes that have been silenced in cancer cells. The drug may also enhance immune recognition of tumors by upregulating antigen presentation and immune checkpoint molecules.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.